Aims and Scope

HemaSphere publishes results of highly relevant basic, translational, and clinical research in hematology. We are especially looking for strong studies reporting novel findings that are of high impact to the field of hematology.

Review articles and guideline articles provide clear overviews and discussions of new developments as well as recommendations for patient care.

HemaSphere​ is the premier hematology information ​​resource, which is enhanced by the HemaTopics and HemaPolicy sections of the journal. These sections provide insightful discussions on all aspects related to hematology, including summaries of important articles, reports of ne​w therapies, discussions on European policy, and other hematology news items. HemaSphere is guided by Editor in Chief​ Jan Cools and Deputy Editor in Chief Claire Harrison​. The Editors and Editorial Board of HemaSphere are international research and clinical leaders, representing a diverse range of areas of hema​​tologic expertise.​​

Impact Factor and Citation Metrics

HemaSphere is proud to have a 2023 Journal Impact Factor (JIF) of 11.9 (source: Journal Citation Reports, Clarivate).

HemaSphere also has a Scopus 2023 CiteScore of 6.1.

Indexing Information

  • CAS: Chemical Abstracts Service (ACS)
  • Current Contents: Clinical Medicine (Clarivate Analytics)
  • Directory of Open Access Journals (DOAJ)
  • Embase (Elsevier)
  • Science Citation Index Expanded (Clarivate Analytics)
  • SCOPUS (Elsevier)

HemaSphere deposits all articles in PMC (PubMed Central).